Margherita Ambrosini

Margherita Ambrosini

Auto-generated profile, based on publicly available information

Margherita Ambrosini

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
Andrea Sartore-BianchiAndrea Sartore-Bianchi
Andrea Sartore-Bianchi
FPFilippo Pietrantonio
Filippo Pietrantonio
SLSara Lonardi
Sara Lonardi
BMBenedetta Mussolin
Benedetta Mussolin
FRFrancesco Rua
Francesco Rua
ABAlberto Bardelli
Alberto Bardelli
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that RAS, BRAF and EGFR mutant alleles, which appear in circulating tumor DNA (ctDNA) during EGFR blockade, decline upon therapy withdrawal. We hypothesized that monitoring resistance mutations in blood could rationally guide subsequent therapy with anti-EGFR antibodies. We report here the results of CHRONOS, an open-label, single-arm phase 2 clinical trial exploiting blood-based identification of RAS/BRAF/EGFR mutations levels to tailor a chemotherapy-free anti-EGFR rechallenge with panitumumab (ClinicalTrials.gov: NCT03227926; EudraCT 2016-002597-12). The primary endpoint was objective response rate. Secondary endpoints were progression-free survival, overall survival, safety and tolerability of this strategy. In CHRONOS, patients with tissue-RAS WT tumors after a previous treatment with anti-EGFR-based regimens underwent an interventional ctDNA-based screening. Of 52 patients, 16 (31%) carried at least one mutation conferring resistance to anti-EGFR therapy and were excluded. The primary endpoint of the trial was met; and, of 27 enrolled patients, eight (30%) achieved partial response and 17 (63%) disease control, including two unconfirmed responses. These clinical results favorably compare with standard third-line treatments and show that interventional liquid biopsies can be effectively and safely exploited in a timely manner to guide anti-EGFR rechallenge therapy with panitumumab in patients with mCRC. Further larger and randomized trials are warranted to formally compare panitumumab rechallenge with standard-of-care therapies in this patient setting.

1 June 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
FCFrancesca Corti
Francesca Corti
SLSara Lonardi
Sara Lonardi
RIRossana Intini
Rossana Intini
MSMassimiliano Salati
Massimiliano Salati
EFElisabetta Fenocchio
Elisabetta Fenocchio
FPFilippo Pietrantonio
Filippo Pietrantonio

22 May 2024 in Annals of Oncology
Verified
Journal Article
Open access
MAM. Ambrosini
M. Ambrosini
BRB. Rousseau
B. Rousseau
PMP. Manca
P. Manca
OAO. Artz
O. Artz
AMA. Marabelle
A. Marabelle
FPFilippo Pietrantonio
Filippo Pietrantonio
POLE and POLD1 proofreading deficiency (POLE/D1pd) define a rare subtype of ultramutated metastatic colorectal cancer (mCRC; over 100 mut/Mb). Disease-specific data about the activity and efficacy of immune checkpoint inhibitors (ICIs) in POLE/D1pd mCRC are lacking and it is unknown whether outcomes may be different from mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) mCRCs treated with ICIs. In this global study, we collected 27 patients with mCRC harboring POLE/D1 mutations leading to proofreading deficiency and treated with anti-programmed cell death-ligand 1 alone +/- anti-cytotoxic T-lymphocyte antigen-4 agents. We collected clinicopathological and genomic characteristics, response, and survival outcomes after ICIs of POLE/D1pd mCRC and compared them with a cohort of 610 dMMR/MSI-H mCRC patients treated with ICIs. Further genomic analyses were carried out in an independent cohort of 7241 CRCs to define POLE and POLD1pd molecular profiles and mutational signatures. POLE/D1pd was associated with younger age, male sex, fewer RAS/BRAF driver mutations, and predominance of right-sided colon cancers. Patients with POLE/D1pd mCRC showed a significantly higher overall response rate (ORR) compared to dMMR/MSI-H mCRC (89% versus 54%; P = 0.01). After a median follow-up of 24.9 months (interquartile range: 11.3-43.0 months), patients with POLE/D1pd showed a significantly superior progression-free survival (PFS) compared to dMMR/MSI-H mCRC [hazard ratio (HR) = 0.24, 95% confidence interval (CI) 0.08-0.74, P = 0.01] and superior overall survival (OS) (HR = 0.38, 95% CI 0.12-1.18, P = 0.09). In multivariable analyses including the type of DNA repair defect, POLE/D1pd was associated with significantly improved PFS (HR = 0.17, 95% CI 0.04-0.69, P = 0.013) and OS (HR = 0.24, 95% CI 0.06-0.98, P = 0.047). Molecular profiling showed that POLE/D1pd tumors have higher tumor mutational burden (TMB). Responses were observed in both subtypes and were associated with the intensity of POLE/D1pd signature. Patients with POLE/D1pd mCRC showed more favorable outcomes compared to dMMR/MSI-H mCRC to treatment with ICIs in terms of tumor response and survival.

3 April 2025 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
MAMargherita Ambrosini
Margherita Ambrosini
PMPaolo Manca
Paolo Manca
VNVincenzo Nasca
Vincenzo Nasca
CSCarolina Sciortino
Carolina Sciortino
FGFilippo Ghelardi
Filippo Ghelardi
FPFilippo Pietrantonio
Filippo Pietrantonio

31 March 2023 in European Journal of Cancer
Verified
Journal Article
Closed access
PMPaolo Manca
Paolo Manca
FCFrancesca Corti
Francesca Corti
RIRossana Intini
Rossana Intini
GMGiacomo Mazzoli
Giacomo Mazzoli
RMRosalba Miceli
Rosalba Miceli
FPFilippo Pietrantonio
Filippo Pietrantonio

11 May 2022 in JCO Precision Oncology
Verified
Journal Article
Open access
GRGiovanni Randon
Giovanni Randon
GMGiulia Maddalena
Giulia Maddalena
MGMarco Maria Germani
Marco Maria Germani
CPChiara Carlotta Pircher
Chiara Carlotta Pircher
PMPaolo Manca
Paolo Manca
FPFilippo Pietrantonio
Filippo Pietrantonio
PURPOSE: Several uncommon genomic alterations beyond RAS and BRAFV600E mutations drive primary resistance to anti–epidermal growth factor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer (mCRC). Our PRESSING panel (including PIK3CA exon 20/ AKT1/ PTEN mutations, ERBB2/ MET amplifications, gene fusions, and microsatellite instability-high status) represented a paradigm of negative hyperselection with more precise tailoring of EGFR blockade. However, a modest proportion of hyperselected mCRC has intrinsic resistance potentially driven by even rarer genomic alterations. MATERIALS AND METHODS: A prospective data set at three Italian Academic Hospitals included 650 patients with mCRC with comprehensive genomic profiling by FoundationOne CDx and treated with anti-EGFRs. PRESSING2 panel alterations were selected on the basis of previous clinico-biologic studies and included NTRKs, ERBB3, NF1, MAP2K1/ 2/ 4, AKT2 pathogenic mutations; PTEN/ NF1 loss; ERBB3, FGFR2, IGF1R, KRAS, ARAF, and AKT1-2 amplification; and EGFR rearrangements. These were collectively associated with outcomes in patients with hyperselected disease, ie, RAS/ BRAF wild-type, PRESSING-negative, and microsatellite stable. RESULTS: Among 162 hyperselected patients, 24 (15%) had PRESSING2 alterations, which were mutually exclusive except in two samples and were numerically higher in right-sided versus left-sided cancers (28% v 13%; P = .149). Independently of sidedness and other factors, patients with PRESSING2-positive status had significantly worse progression-free survival and overall survival compared with PRESSING2-negative ones (median progression-free survival: 6.4 v 12.8 months, adjusted hazard ratio 4.19 [95% CI, 2.58 to 6.79]; median overall survival: 22.6 v 49.9 months, adjusted hazard ratio 2.98 [95% CI, 1.49 to 5.96]). The combined analysis of primary tumor sidedness and PRESSING2 status allowed us to better stratify outcomes. CONCLUSION: Negative ultraselection warrants further investigation with the aim of maximizing the benefit of EGFR blockade strategies in patients with RAS and BRAF wild-type, microsatellite stable mCRC.